SEC Form 4 · accession 0001209191-15-080280
ReShape Lifesciences Inc. · RSLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark B Knudson
Officer — Chrmn, Pres & CEO · Director
Period of report
Nov 12, 2015
Accepted (ET)
Nov 16, 2015 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 12, 2015 | P | 310,000 | $0.161 | A | 613,000 | D | |
| Common Stock | holding | — | — | — | 1,382 | I | Spouse Revocable Trust | |
| Common Stock | holding | — | — | — | 3,215 | I | Family Limited Partnership | |
| Common Stock | holding | — | — | — | 57,571 | I | Revocable Trust 2003 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.76 | holding | — | — | — | — | Apr 27, 2015 | Common Stock | 7,915 | 7,915 | D |
| Stock Option (right to buy)F2 | $2.76 | holding | — | — | — | — | Apr 20, 2016 | Common Stock | 6,776 | 6,776 | D |
| Stock Option (right to buy)F3 | $1.90 | holding | — | — | — | Oct 29, 2010 | Oct 29, 2017 | Common Stock | 33,432 | 33,432 | D |
| Stock Option (right to buy)F3 | $1.90 | holding | — | — | — | Oct 29, 2010 | Oct 29, 2017 | Common Stock | 25,902 | 25,902 | D |
| Stock Option (right to buy)F3 | $1.90 | holding | — | — | — | Oct 29, 2010 | Oct 29, 2017 | Common stock | 44,131 | 44,131 | D |
| Stock Option (right to buy)F3 | $1.90 | holding | — | — | — | Oct 29, 2010 | Oct 29, 2017 | Common Stock | 50,472 | 50,472 | D |
| Stock Option (right to buy)F2 | $3.78 | holding | — | — | — | — | Nov 18, 2019 | Common Stock | 20,833 | 20,833 | D |
| Warrant (common stock right to buy)F4,F5 | $2.19 | holding | — | — | — | — | — | Common Stock | 25,000 | 25,000 | D |
| Stock Option (right to buy)F6 | $2.58 | holding | — | — | — | Mar 16, 2011 | Feb 16, 2021 | Common Stock | 350,000 | 350,000 | D |
| Stock Option (right to buy)F6 | $2.67 | holding | — | — | — | Aug 12, 2011 | Jul 12, 2021 | Common Stock | 350,000 | 350,000 | D |
| Stock Option (right to buy)F6 | $1.90 | holding | — | — | — | Jan 14, 2012 | Dec 14, 2021 | Common Stock | 200,000 | 200,000 | D |
| Stock Option (right to buy)F7,F6 | $3.35 | holding | — | — | — | Aug 10, 2012 | Jul 10, 2022 | Common Stock | 1,292,225 | 1,292,225 | D |
| Stock Option (right to buy)F6 | $1.31 | holding | — | — | — | Jun 30, 2013 | May 31, 2013 | Common Stock | 1,278,730 | 1,278,730 | D |
| Stock Option (right to buy)F6 | $1.11 | holding | — | — | — | Apr 9, 2015 | Mar 9, 2025 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The price reported is the weighted average purchase price for the transaction reported. The purchase prices ranged from $0.15 to $0.18. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range.
- F2Options currently 100% vested.
- F3Options vest 33% on date noted and thereafter at 1/24th per month.
- F4Warrant becomes exercisable 181 days from the date of issuance at close of offering.
- F5Warrant expires five years from the date it becomes exercisable.
- F6Vests in increments of 1/48th per month, beginning the date shown.
- F7The exercise price is the closing price on July 10, 2012, the date the board authorized the grants subject to stockholder approval of the increase in the number of shares available for awards under the incentive plan, which was obtained on September 27, 2012.